arsenic has been researched along with Leucocythaemia in 133 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 22 (16.54) | 18.7374 |
1990's | 9 (6.77) | 18.2507 |
2000's | 61 (45.86) | 29.6817 |
2010's | 34 (25.56) | 24.3611 |
2020's | 7 (5.26) | 2.80 |
Authors | Studies |
---|---|
Fang, J; Shi, D; Song, ZL; Xu, Q; Yao, X; Zhang, J | 1 |
Manley, PW | 1 |
Gao, LX; Liu, TT; Liu, Y; Liu, YJ; She, WY; Shi, XM | 1 |
Bai, Y; Guo, Q; Liu, W; Wang, L | 1 |
Chen, S; Lv, X; Yu, J; Zhang, L | 1 |
Watts, G | 1 |
Hai, Y; Li, H; Li, J; Li, Y; Song, P; Wang, X; Xie, Q; Zhao, L | 1 |
Feng, L; Jiang, W; Li, Y; Shan, N; Wang, X | 1 |
Wang, YS; Wei, HL; Zhou, ST | 1 |
Cui, J; Lin, S; Yang, H | 1 |
Cai, D; Dong, WW; Gao, F; Liu, J; Sun, K; Wang, W; Wang, Y; Zheng, Z | 1 |
Liu, Y; Ren, X; Wang, D; Yu, R; Zeng, L | 1 |
Diamantidis, MD; Papaioannou, M | 1 |
Benbijja, M; Bobé, P; Mellouk, A | 1 |
Inomata, T; Sunami, K | 1 |
Kong, P; Ma, Y; Shen, Z; Yang, S; Zeng, D; Zhang, X; Zou, Z | 1 |
Li, Y; Liu, J; Ma, X; Ye, BC; Zhang, B; Zuo, P | 1 |
Fan, J; Guo, K; Li, Y; Li, Z; Weng, G; Wu, J; Xia, P; Zeng, Y; Zheng, R | 1 |
Ai, Z; Chen, J; Cheng, J; Lin, L; Liu, Z; Wang, B; Wei, H; Xie, B; Yang, Y; Yi, J; Zhao, H | 1 |
Li, H; Sun, H; Zhou, Y | 1 |
Dong, J; Jing, Y; Wang, R; Xu, L; Yu, Z | 1 |
Aller, P; Amrán, D; de Blas, E; Fernández, C; Sánchez, Y | 1 |
Cen, J; Chen, Z; Gu, M; Liu, D; Qi, X | 1 |
Chen, T; Fu, YL | 1 |
Ahuja, HG; Bailey, HH; Chang, JE; Kahl, BS; Kim, K; Kolesar, JM; Rodriguez, GA; Sanchez, FA; Voorhees, PM; Werndli, J | 1 |
MOESCHLIN, S | 1 |
JUDD, T; KIRSCHBAUM, A | 1 |
Lin, TH; Lu, FJ; Tseng, TH; Yin, YF | 1 |
Bowling, B; Doudican, NA; Orlow, SJ | 1 |
Cao, YX; Hao, JX; Li, J; Liu, SX | 1 |
Chen, B; Guo, D; Jiang, H; Song, W; Wang, X; Wu, C | 1 |
Jiang, J; Liu, XS; Peng, CY; Zheng, HT | 1 |
Bachleitner-Hofmann, T; Roth, E; Sturlan, S; Wessner, B; Wirtitsch, M | 1 |
Essers, MA; Trumpp, A | 1 |
Beitz, E; Mukhopadhyay, R | 1 |
Chen, L; Dong, Z; Meng, Q; Peng, Z; Si, J; Xia, Y | 1 |
Chung, JG; Huang, WW; Kuo, SC; Lai, IC; Lai, TY; Lin, CC; Lin, JJ; Wen, YF; Yang, JS | 1 |
Chen, G; Ho, PC; Liu, J; Shao, Y; Wu, J | 1 |
Arkusz, J; Ferlińska, M; Gradecka-Meesters, D; Smok-Pieniążek, A; Stańczyk, M; Stępnik, M | 1 |
Tang, X; Wang, C; Xiao, G; Yao, C | 1 |
Balayssac, S; Ballot, C; Briand, G; Dammak, A; Dauphin, V; Formstecher, P; Idziorek, T; Jendoubi, M; Joha, S; Jonneaux, A; Kluza, J; Maboudou, P; Malet-Martino, M; Marchetti, P; Quesnel, B | 1 |
Aller, P; Boyano-Adánez, Mdel C; Bréard, J; Calviño, E; de Blas, E; Estañ, MC; Sancho, P; Simón, GP | 1 |
Kwong, YL | 1 |
Liu, J; Liu, Y; Qu, J; Qu, X; Xu, L; Zhang, G; Zhang, Y; Zheng, H | 1 |
Chin, A; Ciancaglini, P; de Oliveira, KT; dos Santos, GA; Faça, VM; Falcão, RP; Ferreira, GA; Greene, LJ; Hanash, SM; Izumi, C; Leopoldino, AM; Rego, EM; Scheucher, PS; Simão, AM; Thomé, CH | 1 |
Aller, P; Boyano-Adánez, Mdel C; Calviño, E; de Blas, E; Estañ, MC; Gómez-Gómez, M; Mena, ML; Rial, E | 1 |
Chen, SY; Li, XM; Liu, SX | 1 |
Chang, IY; Hsieh, RK; Huang, MJ; Lin, CP; Liu, HJ | 1 |
Liu, XP; Narla, RK; Uckun, FM | 1 |
Bachleitner-Hofmann, T; Baumgartner, M; Roth, E; Sturlan, S | 1 |
Stull, DM | 1 |
An, S; Bae, IJ; Gwak, HS; Hong, SI; Lee, HC; Lee, SH; Park, IC; Park, MJ; Rhee, CH; Seo, KM; Woo, SH | 1 |
LEBON, J; MESSERSCHMITT, J | 1 |
Bai, D; Ge, J; Ma, L; Su, H; Wang, B; Wei, H; Yao, X; Zhao, H | 1 |
Shen, WL; Zhang, Y | 1 |
ENGLE, RL; LOTT, WA; REZNIKOFF, P; YALE, HL | 1 |
Lin, MF; Wei, GQ; Zhang, SL; Zou, DB | 1 |
Antony, S; Fu, H; Kohlhagen, G; Liao, Z; Liu, H; Pommier, Y; Sordet, O; Stevens, EV | 1 |
Billi, AM; Cappellini, A; Cocco, L; Falà, F; Manzoli, L; Martelli, AM; Tabellini, G; Tazzari, PL | 1 |
Pan, B; Xu, L; Yang, X | 1 |
Ma, H; Wang, C; Wang, XF; Wang, Y | 1 |
FLORIJN, E | 1 |
Chen, G; Chen, L; Chen, S; Li, X; Ni, J; Shen, Z; Tang, W; Wang, Z; Xiong, S; Zhong, H; Zhu, J | 1 |
Chen, SJ; Chen, Z; Dong, Y; Fang, J; Hu, J | 1 |
Liu, SX; Liu, Y; Ren, LF; Xiao, YF | 1 |
Baccarani, M; Billi, AM; Bortul, R; Evangelisti, C; Grafone, T; Martelli, AM; Martinelli, G; Tabellini, G; Tazzari, PL | 1 |
Cahill, S; Meyer, M; O'Dwyer, M; Samali, A; Szegezdi, E | 1 |
Chen, GQ; Huang, Y; Jiang, Y; Liu, W; Peng, ZG; Song, LP; Zhao, Q | 1 |
Jing, Y; Waxman, S; Wurmbach, E; Xia, L | 1 |
Moore, P; Tchounwou, PB; Yedjou, CG | 1 |
Meng, L; Meng, R; Sui, XH; Yang, BF; Zhou, J | 1 |
Duan, LN; Guo, ZK; Ji, SQ; Wang, HX | 1 |
Bauer, N; Bergmann, L; Chow, KU; Glienke, W | 1 |
Aller, P; Amrán, D; de Blas, E; Esteban, D; Fernandez, C; Palacios, MA; Ramos, AM | 1 |
Chan, R; Chen, D; Jing, Y; Waxman, S | 1 |
Seo, T; Ueda, T; Urasaki, Y | 1 |
Cui, X; Liu, T; Meng, WT; Xi, YM; Ye, XS | 1 |
Li, W; Meng, R; Sui, X; Yang, B; Zhou, J | 1 |
Aoki, M; Arai, A; Ichijo, H; Miura, O; Yan, W | 1 |
Astier, A; Gibaud, S | 1 |
Chen, GQ; Li, D; Liu, W; Wang, Y; Wang, YC; Wu, YL; Yan, H | 1 |
Berman, JN; Look, AT | 1 |
Czyz, M; Duechler, M; Stańczyk, M; Stepnik, M | 1 |
Chen, JP; Cong, YW; Dong, B; Fu, YL; Huang, R; Liang, YG; Liu, ZY; Mao, BZ; Shan, YJ; Wang, SQ; Xiao, H; Yu, ZY; Zhao, QS; Zhao, ZH | 1 |
Hampton, T | 1 |
Aller, P; Amrán, D; Bréard, J; Calle, C; de Blas, E; Fernández, C; Ramos, AM; Sánchez, Y | 1 |
Chen, FY; Han, JY; Huang, HH; Wang, HR; Zhong, H; Zhong, JH; Zhu, JY | 1 |
Chen, GQ; Wang, LS; Wu, YL; Yu, Y | 1 |
Chen, SJ; Chen, Z; Li, G; Zhou, GB | 1 |
Chen, SY; Dong, Y; Guo, WJ; Ma, LH; Wang, ZY | 1 |
Cai, YX; Fu, YB; Li, L; Meng, FY; Sun, QX | 1 |
TROPEANO, L | 1 |
Aller, P; Ramos, AM | 1 |
Ayzac, L; Bergeret, A; Bonhomme, I; Dananche, B; Fabry, J; Fevotte, J; Fière, D; Hours, M; Milan, JJ; Philippe, J | 1 |
Birchall, D; Farmer, P; Goldman, J; Meller, S; Piller, G; Treleaven, J | 1 |
Kwong, YL; Todd, D | 1 |
Adami, HO; Dich, J; Hanberg, A; Zahm, SH | 1 |
Conrad, ME | 1 |
Akao, Y; Nakagawa, Y; Yamada, H | 1 |
Cheson, BD; McBee, WL; Murgo, AJ | 1 |
Dias, S; Lam, G; Lane, WJ; Rafii, S; Roboz, GJ; Soignet, SL; Warrell, RP | 1 |
Bhalla, KN; Nguyen, D; Nimmanapalli, R; Perkins, C; Porosnicu, M; Worthington, E | 1 |
Bruey, JM; Corcos, L; Garrido, C; Leroy, I; Lizard, G; Miguet, C; Plenchette, S; Rébé, C; Solary, E; Sordet, O | 1 |
Barbey, JT | 1 |
Singer, JW | 1 |
Cai, X; Chen, G; Shen, Y | 1 |
Buyukececi, F; Omay, SB; Sanli, UA; Saydam, G; Terzioglu, E; Uslu, R; Yuksel, S | 1 |
Chen, GQ; Chen, SJ; Chen, Z; Shen, ZX; Sun, GL; Tong, JH; Wang, ZY | 1 |
Callas, P; Eskenazi, B; Harrison, R; Sharp, DS; Smith, AH | 1 |
Gordon, HL; Holder, BB; Ott, MG | 1 |
Jondorf, WR | 1 |
Gao, Z; He, Y; Hu, Y; Li, F; Li, H; Li, Y; Liu, L; Ma, D; Ma, G; Shi, J; Wang, C; Wang, S; Wei, W; Yu, S; Yue, H; Zhang, W; Zhao, C; Zhou, W | 1 |
Cheng, YY; Guo, HR; Li, CY; Lin, MH | 1 |
Cai, X; Jiang, M; Jiang, Y; Li, Y; Ma, X; Meng, G; Tan, Y; Wu, W; Yin, H; Yin, T; Zhang, H | 1 |
Ahangaran, N; Doosti-Irani, A; Khamutian, S; Khodabakhshi, M; Rahmani, A; Sahraeei, F; Shirmohammadi-Khorram, N; Shokoohizadeh, MJ | 1 |
Li, H; Sun, H; Tse, E; Wang, H; Zhou, Y | 1 |
Chen, SJ; Chen, Z; de Thé, H; Mao, JH; Zhang, XW; Zhou, GB | 1 |
BLOCK, M; JACOBSON, LO; NEAL, W | 1 |
MARCHAL, G | 1 |
MARINO, A; PREZIOSI, P | 1 |
KISELEVA, AN; KUZ'MIN, DS; POVERGO, NS; ROZANOVA, LM; SHERMAN, SI; VAKULENKO, AD | 2 |
BIRCHALL, R; CHRISTIANSON, HB | 1 |
TARCHIANI, G; VITALE, S | 1 |
HEISTER, B; NORDQVIST, P | 1 |
BLOCK, MH; JACOBSON, LO | 1 |
Grünwald, HW; Rosner, F | 1 |
Kjellson, L | 1 |
Zeng, H | 1 |
Hahn, GM; Mivechi, NF; Monson, JM | 1 |
Kohno, H; Taketani, S; Tokunaga, R; Yoshinaga, T | 1 |
Philipp, R | 1 |
Kobylinski, S | 1 |
22 review(s) available for arsenic and Leucocythaemia
Article | Year |
---|---|
[Research of traditional Chinese medicine in the treatment of leukemia: current status].
Topics: Arsenic Trioxide; Arsenicals; Diagnosis, Differential; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Humans; Leukemia; Medicine, Chinese Traditional; Oxides; Phytotherapy | 2008 |
Targeting leukemic stem cells by breaking their dormancy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Granulocyte Colony-Stimulating Factor; Humans; Interferon-alpha; Leukemia; Neoplastic Stem Cells; Oxides | 2010 |
Metalloid transport by aquaglyceroporins: consequences in the treatment of human diseases.
Topics: Animals; Aquaglyceroporins; Aquaporins; Arsenicals; Biological Transport; Humans; Leukemia; Metals; Models, Biological; Neoplasms; Parasites; Parasitic Diseases; Permeability | 2010 |
The medicinal use of realgar (As₄S₄) and its recent development as an anticancer agent.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; History, 16th Century; History, 19th Century; History, 20th Century; History, 21st Century; History, Ancient; History, Medieval; Humans; Leukemia; Medicine, Traditional; Oxides; Sulfides | 2011 |
Pathogenesis and treatment of leukemia: an Asian perspective.
Topics: Arsenic Trioxide; Arsenicals; Asian People; Cell Proliferation; Humans; Leukemia; Leukemia, Large Granular Lymphocytic; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2012 |
[A review of the research on malignant hemopathies treated with arsenium-containing Chinese drugs].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Materia Medica; Oxides; Sulfides; Tumor Cells, Cultured | 2000 |
Targeted therapies for the treatment of leukemia.
Topics: Alemtuzumab; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Dose-Response Relationship, Drug; Drug Interactions; Gemtuzumab; Humans; Imatinib Mesylate; Leukemia; Nurse-Patient Relations; Nurse's Role; Oncology Nursing; Oxides; Patient Education as Topic; Piperazines; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Tretinoin | 2003 |
[Advances in the study on antineoplastic action of realgar].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; K562 Cells; Leukemia; Leukemia, Promyelocytic, Acute; Materia Medica; Oxides; Tumor Cells, Cultured | 2004 |
Arsenic in cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenicals; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Leukemia; Lymphoma; Multiple Myeloma | 2005 |
Hypoxia inducible factor-1alpha and leukemic cell differentiation.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia; Leukemia, Promyelocytic, Acute; Oxides | 2006 |
Targeting transcription factors in acute leukemia in children.
Topics: Acute Disease; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; DNA Methylation; Drug Delivery Systems; Histone Deacetylase Inhibitors; Humans; Leukemia; Oxides; Transcription Factors; Tretinoin | 2007 |
Leukemia, an effective model for chemical biology and target therapy.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Dasatinib; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tretinoin | 2007 |
From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Disease Models, Animal; Humans; Imatinib Mesylate; Leukemia; Oxides; Piperazines; Pyrimidines; Tretinoin | 2007 |
Pesticides and cancer.
Topics: Animals; Arsenicals; Breast Neoplasms; Carcinogens; Causality; Chlordan; Creosote; DDT; Ditiocarb; Female; Herbicides; Hexachlorocyclohexane; Humans; Insecticides; Leukemia; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Mutagens; Neoplasms; Neoplasms, Experimental; Occupational Diseases; Occupational Exposure; Ovarian Neoplasms; Pesticides; Phenols; Protective Devices; Sarcoma; Triazines | 1997 |
Arsenic-induced apoptosis in malignant cells in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Down-Regulation; Glutathione; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, B-Cell; Leukemia, Promyelocytic, Acute; Leukocytes, Mononuclear; Neuroblastoma; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2000 |
Cardiac toxicity of arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Artifacts; Electrocardiography; Electrolytes; Humans; Leukemia; Long QT Syndrome; Oxides; Torsades de Pointes | 2001 |
Expanding the use of arsenic trioxide: leukemias and beyond.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Neoplasms; Oxides | 2002 |
Delayed health hazards of pesticide exposure.
Topics: 2,4-Dichlorophenoxyacetic Acid; 2,4,5-Trichlorophenoxyacetic Acid; Agent Orange; Agricultural Workers' Diseases; Amitrole; Arsenicals; Chlorophenols; Dioxins; Europe; Herbicides; Humans; Insecticides; Leukemia; Neoplasms; Nervous System Diseases; New Zealand; Occupational Diseases; Organophosphate Poisoning; Pesticides; Polychlorinated Dibenzodioxins; Propane; Reproduction; Risk; Sweden; Time Factors; United States; Vietnam | 1986 |
From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia.
Topics: Adult; Animals; Arsenic; Humans; Leukemia; Magic; Medicine, Traditional; Models, Biological; Models, Molecular; Signal Transduction; Treatment Outcome | 2011 |
[INORGANIC ARSENIC IN THERAPY (WITH PARTICULAR ATTENTION TO ANTILEUKEMIC THERAPY)].
Topics: Arsenic; Attention; Drug Therapy; Leukemia; Neoplasms; Toxicology | 1964 |
Cytotoxic drugs and leukaemogenesis.
Topics: Adult; Aged; Arsenic; Benzene; Bone Marrow; Breast Neoplasms; Female; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Mycosis Fungoides; Ovarian Neoplasms; Paraproteinemias; Waldenstrom Macroglobulinemia | 1980 |
Arsenic exposure: health effects and the risk of cancer.
Topics: Absorption; Arsenic; Arsenic Poisoning; Diet; Gastrointestinal Neoplasms; Humans; Kidney Neoplasms; Leukemia; Liver Neoplasms; Mutagens; Neoplasms; Occupational Diseases; Respiratory Tract Neoplasms; Risk; Skin Neoplasms; Teratogens | 1985 |
2 trial(s) available for arsenic and Leucocythaemia
Article | Year |
---|---|
Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study.
Topics: Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Female; Glutathione; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Oxides; Safety | 2009 |
Effects of arsenic trioxide administration styles on leukocytosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Humans; Infusions, Intravenous; K562 Cells; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides | 2006 |
109 other study(ies) available for arsenic and Leucocythaemia
Article | Year |
---|---|
Structural Modification of Aminophenylarsenoxides Generates Candidates for Leukemia Treatment
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; HL-60 Cells; Humans; Leukemia; Molecular Docking Simulation; Molecular Structure; Oxidative Stress; Reactive Oxygen Species; Structure-Activity Relationship; Thioredoxin-Disulfide Reductase | 2021 |
Evidence supporting that the attribution of first success in use of arsenic for the treatment of leukaemia should be to David Lissauer (1836-1892).
Topics: Arsenic; Arsenicals; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Oxides | 2022 |
1,3-Benzodioxole Derivatives Improve the Anti-Tumor Efficiency of Arsenicals.
Topics: Animals; Apoptosis; Arsenicals; Dioxoles; Leukemia; Mice; Neoplasms | 2022 |
A proteomics research of apoptosis of leukemia cells induced by arsenic trioxide.
Topics: Amino Acid Sequence; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Shape; HL-60 Cells; Humans; Leukemia; Mass Spectrometry; Neoplasm Proteins; Oxides; Proteomics | 2017 |
HOXA9 is critical in the proliferation, differentiation, and malignancy of leukaemia cells both in vitro and in vivo.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Down-Regulation; HL-60 Cells; Homeodomain Proteins; Humans; Leukemia; Male; Mice; Mice, Nude; MicroRNAs; Oxides; RNA Interference; RNA, Messenger; Transplantation, Heterologous; Tretinoin | 2017 |
Guo-Qiang Chen: haematologist who risked all for research success.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biomedical Research; China; Hematology; History, 20th Century; History, 21st Century; Humans; Leukemia; Oxides; Portraits as Topic | 2018 |
Realgar transforming solution as a novel arsenic agent with a lower risk of cardiotoxicity.
Topics: Animals; Arsenicals; Cardiotoxicity; Cell Proliferation; Cells, Cultured; Female; Humans; Leukemia; Long QT Syndrome; Male; Mice; Rats, Wistar; Risk; Solutions; Sulfides | 2019 |
Artesunate possesses anti-leukemia properties that can be enhanced by arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Artemisinins; Artesunate; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Fas Ligand Protein; fas Receptor; Humans; K562 Cells; Leukemia; Oxides; Proto-Oncogene Proteins c-fos; U937 Cells | 2014 |
[Apoptosis effects of drug sensitivity leukemia cells induced by nano-realgar].
Topics: Apoptosis; Arsenicals; Cell Proliferation; Humans; K562 Cells; Leukemia; Nanotechnology; Proto-Oncogene Proteins c-bcl-2; Sulfides; Tumor Suppressor Protein p53 | 2013 |
Identifying arsenic trioxide (ATO) functions in leukemia cells by using time series gene expression profiles.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cluster Analysis; Computational Biology; Databases, Nucleic Acid; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Leukemia; Molecular Sequence Annotation; Oxides; Time Factors; Transcriptome | 2014 |
Investigation of the mechanism involved in the As2O3-regulated decrease in MDR1 expression in leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Binding Sites; Cell Line, Tumor; Drug Resistance, Neoplasm; HEK293 Cells; Humans; I-kappa B Kinase; K562 Cells; Leukemia; Molecular Sequence Data; Oxides; Phosphorylases; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Sequence Analysis, DNA; Signal Transduction; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2014 |
The growth-inhibitory and apoptosis-inducing effect of deferoxamine combined with arsenic trioxide on HL-60 xenografts in nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Deferoxamine; Female; HL-60 Cells; Humans; Leukemia; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; Xenograft Model Antitumor Assays | 2014 |
Toward adjunctive therapy of acute myeloid leukemia: is it feasible?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Deferoxamine; Female; Humans; Leukemia; Oxides | 2014 |
Sensitivity of leukemic T-cell lines to arsenic trioxide cytotoxicity is dependent on the induction of phosphatase B220/CD45R expression at the cell surface.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Death; Cell Line, Tumor; Cell Membrane; HSP70 Heat-Shock Proteins; Humans; Jurkat Cells; Leukemia; Leukocyte Common Antigens; Mice; Mice, Inbred MRL lpr; NF-kappa B; Oxides; T-Lymphocytes | 2014 |
[Antileukemic].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Humans; Leukemia; Oxides; Remission Induction; Tetrahydronaphthalenes; Tretinoin | 2015 |
[Effect of arsenic trioxide on proliferation and apoptosis of human leukemia cell line MV4-11 cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; Leukemia; Oxides | 2015 |
Ultrasensitive and selective assay of glutathione species in arsenic trioxide-treated leukemia HL-60 cell line by molecularly imprinted polymer decorated electrochemical sensors.
Topics: Acetylcysteine; Arsenic Trioxide; Arsenicals; Biosensing Techniques; Dielectric Spectroscopy; Glutathione; Glutathione Disulfide; HL-60 Cells; Humans; Leukemia; Molecular Imprinting; Oxides; Polymers | 2016 |
Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; Curcumin; Down-Regulation; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Leukemia; Myelodysplastic Syndromes; Oxides; Poly(ADP-ribose) Polymerases; RNA, Small Interfering; Stem Cells; Survivin | 2016 |
Differential expression and response to arsenic stress of MRPs and ASAN1 determine sensitivity of classical multidrug-resistant leukemia cells to arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Arsenite Transporting ATPases; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression; HL-60 Cells; Humans; K562 Cells; Leukemia; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Oxides | 2016 |
Cytotoxicity of arsenic trioxide in single leukemia cells by time-resolved ICP-MS together with lanthanide tags.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Death; Cell Differentiation; Cell Line, Tumor; Cisplatin; HL-60 Cells; Humans; Lanthanoid Series Elements; Leukemia; Mass Spectrometry; Oxides; Single-Cell Analysis; Time Factors | 2017 |
N-(beta-Elemene-13-yl)tryptophan methyl ester induces apoptosis in human leukemia cells and synergizes with arsenic trioxide through a hydrogen peroxide dependent pathway.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Catalase; Cell Proliferation; Cell Survival; Drug Synergism; HL-60 Cells; Humans; Hydrogen Peroxide; Leukemia; Oxides; Sesquiterpenes; Tryptophan | 2008 |
Genistein selectively potentiates arsenic trioxide-induced apoptosis in human leukemia cells via reactive oxygen species generation and activation of reactive oxygen species-inducible protein kinases (p38-MAPK, AMPK).
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Synergism; Electrophoretic Mobility Shift Assay; Enzyme Activation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genistein; HL-60 Cells; Humans; Immunoblotting; Jurkat Cells; Leukemia; Multienzyme Complexes; Oxidative Stress; Oxides; p38 Mitogen-Activated Protein Kinases; Protein Serine-Threonine Kinases; Reactive Oxygen Species; U937 Cells | 2008 |
Expression of Dlk1 gene in myelodysplastic syndrome determined by microarray, and its effects on leukemia cells.
Topics: Adult; Aged; Antigens, CD34; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium-Binding Proteins; Cell Cycle; Cell Proliferation; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; Intercellular Signaling Peptides and Proteins; K562 Cells; Leukemia; Leukocytes, Mononuclear; Male; Membrane Proteins; Middle Aged; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Oxides; Tetradecanoylphorbol Acetate; Up-Regulation | 2008 |
Therapy for Leukemia with X-rays, arsenic and Urethane.
Topics: Arsenic; Arsenicals; Leukemia; Radiotherapy; Urethane | 1948 |
Effect of urethane, X-rays, potassium arsenite, benzol, on survival time in transplanted mouse leukemia.
Topics: Animals; Arsenicals; Arsenites; Benzene; Leukemia; Leukemia, Experimental; Potassium; Potassium Compounds; Urethane; X-Rays | 1948 |
Enhancement of esculetin on arsenic trioxide-provoked apoptosis in human leukemia U937 cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Survival; Fluorescent Antibody Technique; Humans; Leukemia; Oxides; U937 Cells; Umbelliferones | 2009 |
Enhancement of arsenic trioxide cytotoxicity by dietary isothiocyanates in human leukemic cells via a reactive oxygen species-dependent mechanism.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Death; Drug Synergism; Humans; Isothiocyanates; Leukemia; Oxides; Reactive Oxygen Species; Sulfides; Sulfones; Sulfoxides; Thiocyanates; Tumor Cells, Cultured; Vegetables | 2010 |
[Comparison of the effect of arsenic sulfide on apoptosis and hTERT-mRNA expression in two leukemia cell lines].
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenicals; Cell Cycle; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Leukemia; RNA, Messenger; Sulfides; Telomerase | 2009 |
Effect of colloidal gold nanoparticles on cell interface and their enhanced intracellular uptake of arsenic trioxide in leukemia cancer cells.
Topics: Arsenic Trioxide; Arsenicals; Colloids; Electrochemistry; Gold; Humans; K562 Cells; Leukemia; Metal Nanoparticles; Oxides | 2009 |
Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Drug Antagonism; Drug Synergism; Electrophoresis, Capillary; Growth Inhibitors; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; K562 Cells; Leukemia; Oxides; U937 Cells; Valproic Acid | 2010 |
Omega-3 and omega-6 polyunsaturated fatty acids enhance arsenic trioxide efficacy in arsenic trioxide-resistant leukemic and solid tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Arachidonic Acid; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Humans; Leukemia; Lipid Peroxidation; Neoplasms; Oxides; Vitamin E | 2009 |
Nuclear Factor-κB modulates cellular glutathione and prevents oxidative stress in cancer cells.
Topics: Animals; Arsenic Trioxide; Arsenicals; Glutathione; Humans; Leukemia; Male; Mice; NF-kappa B; Oxidative Stress; Oxides; Prostatic Neoplasms; Signal Transduction | 2010 |
Arsenic trioxide (As₂O₃) inhibits murine WEHI-3 leukemia in BALB/c mice in vivo.
Topics: Animals; Antigens, Differentiation; Arsenic Trioxide; Arsenicals; B-Lymphocytes; Cell Differentiation; Cell Line, Tumor; Leukemia; Leukemia, Experimental; Macrophages; Male; Mice; Mice, Inbred BALB C; Oxides; Spleen; Tretinoin | 2012 |
Assessment of the involvement of oxidative stress and Mitogen-Activated Protein Kinase signaling pathways in the cytotoxic effects of arsenic trioxide and its combination with sulindac or its metabolites: sulindac sulfide and sulindac sulfone on human leu
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Glutathione; Humans; Leukemia; Mitogen-Activated Protein Kinases; Oxidative Stress; Oxides; Reactive Oxygen Species; Signal Transduction; Sulindac | 2012 |
Potentiation of arsenic trioxide-induced apoptosis by 8-bromo-7-methoxychrysin in human leukemia cells involves depletion of intracellular reduced glutathione.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Cell Survival; Cytochromes c; Dose-Response Relationship, Drug; Drug Synergism; Flavonoids; Glutathione; HL-60 Cells; Humans; Intracellular Space; Jurkat Cells; Leukemia; Mitochondria; Oxides; Phosphorylation; Proto-Oncogene Proteins c-akt; Time Factors; U937 Cells; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.
Topics: Animals; Arsenic Trioxide; Arsenicals; Benzamides; Cell Death; Cell Line, Tumor; Cell Respiration; Drug Resistance, Neoplasm; Electron Transport; Energy Metabolism; Glucose; Imatinib Mesylate; Isothiocyanates; Leukemia; Mice; Mitochondria; Models, Biological; Oxidative Stress; Oxides; Piperazines; Pyrimidines; Reactive Oxygen Species | 2011 |
Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Indazoles; Leukemia; Membrane Potential, Mitochondrial; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Oxidative Stress; Oxides; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; TOR Serine-Threonine Kinases | 2011 |
Cbl-b-dependent degradation of FLIP(L) is involved in ATO-induced autophagy in leukemic K562 and gastric cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Arsenic Trioxide; Arsenicals; Autophagy; Base Sequence; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Cell Survival; Humans; Jurkat Cells; K562 Cells; Leukemia; Oxides; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-cbl; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; Ubiquitin | 2012 |
Linker for activation of T-cell family member2 (LAT2) a lipid raft adaptor protein for AKT signaling, is an early mediator of alkylphospholipid anti-leukemic activity.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line; Cell Proliferation; Cholesterol; Enzyme Activation; Humans; Leukemia; Membrane Microdomains; Oxides; Phosphatidylinositol 3-Kinases; Phospholipids; Phosphorylcholine; Protein Structure, Tertiary; Proteome; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Signal Transduction | 2012 |
2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/AMPK signaling pathways.
Topics: Adenosine Triphosphate; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; Cell Line, Tumor; Deoxyglucose; Humans; Leukemia; Mitochondria; Oxidative Stress; Oxides; Protein Kinase Inhibitors; Protein Kinases; Receptor, IGF Type 1; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
The cytotoxicity of arsenic trioxide to normal hematopoietic progenitors and leukemic cells is dependent on their cell-cycle status.
Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Drug Resistance; Flow Cytometry; Hematopoietic Stem Cells; HL-60 Cells; Humans; Immunophenotyping; Interphase; Leukemia; Oxides | 2002 |
Organic phenyl arsonic acid compounds with potent antileukemic activity.
Topics: Antineoplastic Agents; Arsenicals; Cell Lineage; Genes, p53; Humans; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2003 |
Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 3; Caspases; Docosahexaenoic Acids; Drug Interactions; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Leukemia; Lipid Peroxidation; Membrane Potentials; Mitochondria; Oleic Acid; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Tumor Cells, Cultured; Vitamin E | 2003 |
Tetraarsenic oxide induces apoptosis in U937 leukemic cells through a reactive oxygen species-dependent pathway.
Topics: Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Catalase; Cytochromes c; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Hydrogen Peroxide; Leukemia; Membrane Potentials; Mitochondria; Oxides; Reactive Oxygen Species; Time Factors; U937 Cells | 2003 |
[Drug-induced aplastic myelosis; terminal acute myeloblstosis; pathogenic reflections].
Topics: Arsenicals; Chloramphenicol; Humans; Leukemia; Leukemia, Myeloid | 1955 |
Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Multiple; Gene Expression; Genes, MDR; Humans; Leukemia; Oxides | 2003 |
Bcl-2 antisense oligodeoxynucleotide increases the sensitivity of leukemic cells to arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; Cell Line, Tumor; DNA; Dose-Response Relationship, Drug; Flow Cytometry; Genetic Therapy; Humans; K562 Cells; Leukemia; Oligonucleotides, Antisense; Oxides; Proto-Oncogene Proteins c-bcl-2; Time Factors | 2003 |
Comparative effectiveness of five newly synthesized arsenical compounds in treatment of leukemia in mice.
Topics: Animals; Arsenicals; Leukemia; Leukemia, Experimental; Mice | 1952 |
[Cytotoxic effects of arsenic trioxide in combination with chemotherapeutic drugs on acute non-promyelocytic leukemia cells].
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Male; Middle Aged; Oxides | 2004 |
Topoisomerase I-DNA complexes contribute to arsenic trioxide-induced apoptosis.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Buthionine Sulfoximine; Caspase 3; Caspase Inhibitors; Caspases; DNA; DNA Fragmentation; DNA Topoisomerases, Type I; Enzyme Activation; Enzyme Inhibitors; Flow Cytometry; Gene Expression; Gene Silencing; Humans; Leukemia; Oxides; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Recombinant Proteins; Tumor Cells, Cultured | 2004 |
Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells.
Topics: Androstadienes; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Line, Tumor; Chromones; Drug Resistance; Enzyme Activation; Enzyme Inhibitors; HL-60 Cells; Humans; Leukemia; Morpholines; Mutation; NF-kappa B; NF-kappa B p50 Subunit; Oxides; Peptides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphoric Monoester Hydrolases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Transfection; Tumor Suppressor Proteins; Wortmannin | 2005 |
Simultaneously multi-parameter determination of hematonosis cell apoptosis by two-photon and confocal laser scanning microscopy.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Cell Line, Tumor; Cell Nucleus; Dose-Response Relationship, Drug; Flow Cytometry; Hematologic Diseases; Humans; Leukemia; Membrane Potentials; Microscopy, Confocal; Mitochondria; Oxides; Photons | 2004 |
On the action arsenite and urethane in leukaemia and polycythaemia.
Topics: Arsenic; Arsenicals; Arsenites; Humans; Leukemia; Polycythemia; Urethane | 1950 |
[Effects of arsenic trioxide on the subcellular localization of PML/PML-RARalpha protein in leukemic cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; HL-60 Cells; Humans; Intracellular Space; Leukemia; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Protein Transport; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 1997 |
[Effect of realgar on expression of survivin in leukemia cell lines and its significance].
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Blotting, Western; Caspase 3; Dose-Response Relationship, Drug; fas Receptor; Fluorescent Antibody Technique; HL-60 Cells; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Jurkat Cells; Leukemia; Microtubule-Associated Proteins; Neoplasm Proteins; Sulfides; Survivin; Time Factors | 2005 |
Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Flow Cytometry; Humans; In Situ Nick-End Labeling; Jurkat Cells; Leukemia; Leukemia, Promyelocytic, Acute; Leukemia, T-Cell; Oxides; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; RNA, Small Interfering; Signal Transduction; Transfection; Tumor Cells, Cultured | 2005 |
TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Caspase 8; Caspase Inhibitors; Caspases; Cell Line, Tumor; Humans; Leukemia; Membrane Glycoproteins; Oligopeptides; Oncogene Protein v-akt; Oxides; Phosphorylation; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2006 |
Upregulation of Bfl-1/A1 in leukemia cells undergoing differentiation by all-trans retinoic acid treatment attenuates chemotherapeutic agent-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Gene Silencing; HL-60 Cells; Humans; Leukemia; Minor Histocompatibility Antigens; Oxides; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Tretinoin; Up-Regulation | 2006 |
Dose- and time-dependent response of human leukemia (HL-60) cells to arsenic trioxide treatment.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; HL-60 Cells; Humans; Leukemia; Oxides | 2006 |
Arsenic trioxide-responsive leukemia cutis in a patient with acute promyelocytic leukemia after ATRA treatment.
Topics: Adolescent; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Oxides; Risk; Skin; Tretinoin | 2006 |
Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Arsenites; Carrier Proteins; Co-Repressor Proteins; Cytoskeletal Proteins; Gene Expression Regulation; HL-60 Cells; Humans; K562 Cells; Leukemia; Oxides; Sodium Compounds; WT1 Proteins | 2006 |
Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia cells to arsenic trioxide-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Glutathione; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia; Leukemia, Promyelocytic, Acute; Oxides; Peroxides; Reactive Oxygen Species | 2006 |
Buthionine sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2-terminal kinase and up-regulation of death receptors.
Topics: Amino Acid Chloromethyl Ketones; Anthracenes; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Buthionine Sulfoximine; Caspase 3; Caspase Inhibitors; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Glutathione; Humans; Hydrogen Peroxide; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia; Lymphoma; Oxides; Receptors, TNF-Related Apoptosis-Inducing Ligand; Time Factors; U937 Cells | 2006 |
Establishment of an arsenic trioxide-resistant human leukemia cell line that shows multidrug resistance.
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Clone Cells; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia; Multidrug Resistance-Associated Proteins; Oxides; Vincristine | 2007 |
[Methylation of P15INK4B gene in patients with myelodysplastic syndromes and demethylating effects of drugs].
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; Disease Progression; DNA Methylation; Genetic Predisposition to Disease; Humans; Leukemia; Myelodysplastic Syndromes; Oxides | 2007 |
Various tolerances to arsenic trioxide between human cortical neurons and leukemic cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Calcium; Cell Line, Tumor; Cells, Cultured; Cerebral Cortex; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Leukemia; Neurons; Oxides | 2006 |
ASK1 is activated by arsenic trioxide in leukemic cells through accumulation of reactive oxygen species and may play a negative role in induction of apoptosis.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia; MAP Kinase Kinase Kinase 5; Mice; Oxides; p38 Mitogen-Activated Protein Kinases; Reactive Oxygen Species; RNA, Small Interfering | 2007 |
[Organoarsenicals derived from 2-phenyl-[1,3,2]dithiarsolan-4-yl)-methanol (AsIII) with antileukaemic properties: from trypanosomicides to anticancer drugs].
Topics: Animals; Antineoplastic Agents; Arsenicals; Humans; Leukemia; Trypanocidal Agents | 2007 |
Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
Topics: Adult; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Enzyme Activation; Humans; Leukemia; Middle Aged; Mitogen-Activated Protein Kinases; Oxides; Protease Inhibitors; Protein Kinase C-delta; Pyrazines; Tumor Cells, Cultured | 2007 |
Potentiation of arsenic trioxide cytotoxicity by Parthenolide and buthionine sulfoximine in murine and human leukemic cells.
Topics: Adenosine Triphosphate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Death; Cell Line, Tumor; DNA Fragmentation; Drug Synergism; Flow Cytometry; Glutamate-Cysteine Ligase; Glutathione; Humans; Leukemia; Mice; Microscopy, Fluorescence; NF-kappa B; Oxides; Reactive Oxygen Species; Sesquiterpenes | 2008 |
Melissoidesin G, a diterpenoid purified from Isodon melissoides, induces leukemic-cell apoptosis through induction of redox imbalance and exhibits synergy with other anticancer agents.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cytochromes c; Diterpenes; Glutathione; Humans; Isodon; Leukemia; Mitochondria; Molecular Structure; Oxidation-Reduction; Oxides; Phytotherapy; Tumor Cells, Cultured | 2007 |
Cancer agents show first-line potential.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bevacizumab; Dasatinib; Humans; Kidney Neoplasms; Leukemia; Oxides; Pyrimidines; Thiazoles | 2007 |
Arsenic trioxide sensitizes promonocytic leukemia cells to TNFalpha-induced apoptosis via p38-MAPK-regulated activation of both receptor-mediated and mitochondrial pathways.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cytokines; Enzyme Activation; Enzyme Inhibitors; Glutathione; Humans; Leukemia; MAP Kinase Signaling System; Mitochondria; Myeloid Cells; NF-kappa B; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Receptors, Cell Surface; Tumor Necrosis Factor-alpha | 2007 |
[Correlation between expression of apoptosis-related gene pnas-2 and leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Arsenicals; Female; Humans; K562 Cells; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Sulfides; Tumor Cells, Cultured; U937 Cells; Young Adult | 2007 |
[Effects of arsenic trioxide and ATRA on PLZF-RARalpha-positive U937 leukemic cells].
Topics: Antigens, CD; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Proliferation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Transcription Factors; Leukemia; Nitroblue Tetrazolium; Oxidation-Reduction; Oxides; Promyelocytic Leukemia Zinc Finger Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tetracycline; Tretinoin; U937 Cells | 2007 |
[Effect of bortezomib used alone or in combination with arsenic trioxide on HL-60 cell xenograft in nude mice].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Disease Models, Animal; HL-60 Cells; Humans; Leukemia; Male; Mice; Mice, Nude; Oxides; Pyrazines; Random Allocation; Xenograft Model Antitumor Assays | 2007 |
Potassium arsenite, Fowler's arsenical liqueur, in the treatment of chronic leukemic myelosis.
Topics: Amebicides; Antiprotozoal Agents; Antitrichomonal Agents; Arsenic; Arsenicals; Leukemia | 1949 |
Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Cell Line, Tumor; Drug Synergism; Flavonoids; Glutathione; Humans; Leukemia; Membrane Potential, Mitochondrial; Oxides; Protein Kinases; Quercetin | 2008 |
[Occupational exposure and malignant hemopathies: a case-control study in Lyon (France)].
Topics: Adult; Aged; Alkalies; Arsenicals; Case-Control Studies; Dose-Response Relationship, Drug; Dust; Female; Humans; Ink; Leukemia; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mineral Oil; Occupational Exposure; Odds Ratio | 1995 |
Arsenic and Ayurveda.
Topics: Antineoplastic Agents; Arsenicals; Blood Cell Count; Child; History, 19th Century; History, 20th Century; History, Ancient; Humans; India; Keratosis; Leukemia; Medicine, Ayurvedic; Metals; Pigmentation Disorders; Plants, Medicinal; Splenomegaly; Sulfur | 1993 |
Delicious poison: arsenic trioxide for the treatment of leukemia.
Topics: Adult; Antineoplastic Agents; Apoptosis; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cell Differentiation; Fatal Outcome; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Oxides; Splenomegaly | 1997 |
Treatment of acute promyelocytic leukemia with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; History, 16th Century; History, 18th Century; History, 19th Century; History, 20th Century; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction | 1999 |
Clinical trials referral resource. Clinical trials with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Female; Humans; Leukemia; Lymphoma; Multiple Myeloma; Neoplasms; Oxides; Urogenital Neoplasms; Uterine Cervical Neoplasms | 2000 |
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Leukemia; Neovascularization, Pathologic; Oxides; Time Factors | 2000 |
Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Benzamides; Drug Synergism; Fusion Proteins, bcr-abl; Hemoglobins; Humans; Imatinib Mesylate; Leukemia; Macrophage-1 Antigen; Oxides; Piperazines; Protein Serine-Threonine Kinases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein | 2001 |
Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Differentiation; Cell-Free System; Drug Resistance; Etoposide; Humans; Indazoles; Leukemia; Mitochondria; Oxides; Proto-Oncogene Proteins c-bcl-2; Tetradecanoylphorbol Acetate; U937 Cells | 2001 |
Cardiac toxicity of arsenic trioxide.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Approval; Drug Industry; Drug Labeling; Electrocardiography; Electrolytes; Humans; Leukemia; Long QT Syndrome; Oxides; Practice Guidelines as Topic; Safety; Torsades de Pointes; United States; United States Food and Drug Administration | 2001 |
[Glutathione synthesis inhibitor enhances arsenic trioxide-induced apoptosis].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Glutathione; Humans; Leukemia; Lymphoma; Oxides; Tumor Cells, Cultured | 1999 |
Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Dose-Response Relationship, Drug; HL-60 Cells; Humans; K562 Cells; Leukemia; Methylprednisolone; Oxides; Phosphoprotein Phosphatases; Signal Transduction | 2002 |
Respiratory cancer and occupational exposure to arsenicals.
Topics: Adult; Aged; Arsenicals; Cardiovascular Diseases; Dose-Response Relationship, Drug; Environmental Exposure; Female; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Humans; Leukemia; Male; Middle Aged; Occupational Diseases; Respiratory Tract Diseases; Respiratory Tract Neoplasms; Retrospective Studies; Time Factors; Urogenital Neoplasms | 1974 |
A possible unifying principle in the chemotherapy of certain protozoal diseases and of leukemia.
Topics: Amebiasis; Arsenicals; Folic Acid; Folic Acid Antagonists; Humans; Leukemia; Trypanosomiasis, African | 1969 |
Ferritin-based targeted delivery of arsenic to diverse leukaemia types confers strong anti-leukaemia therapeutic effects.
Topics: Adolescent; Adult; Aged; Animals; Antigens, CD; Antineoplastic Agents; Arsenic; Cell Death; Cell Line, Tumor; Child; Drug Delivery Systems; Female; Ferritins; Humans; Leukemia; Male; Mice, SCID; Middle Aged; Nanomedicine; Receptors, Transferrin; Xenograft Model Antitumor Assays; Young Adult | 2021 |
Arsenic in Drinking Water and Incidences of Leukemia and Lymphoma: Implication for Its Dual Effects in Carcinogenicity.
Topics: Arsenic; Carcinogenesis; Drinking Water; Female; Hematologic Neoplasms; Humans; Incidence; Leukemia; Lymphoma; Male; Neoplasms | 2022 |
Phase separation is required for PML nuclear body biogenesis and function.
Topics: Apoptosis; Arsenic; Humans; Leukemia; Promyelocytic Leukemia Nuclear Bodies | 2023 |
The association of arsenic exposure with mortality due to cancer, diabetes, Alzheimer's and congenital anomalies using Poisson regression.
Topics: Alzheimer Disease; Arsenic; Brain Neoplasms; Diabetes Mellitus; Humans; Leukemia | 2023 |
Cell Cycle-Dependent Uptake and Cytotoxicity of Arsenic-Based Drugs in Single Leukemia Cells.
Topics: Antineoplastic Agents; Arsenic; Cell Cycle; Flow Cytometry; Humans; Leukemia; Mass Spectrometry | 2018 |
Biological studies with arsenic. IV. The histopathologic effect of arsenic 76 upon the hematopoietic tissues of patients with leukemia.
Topics: Arsenic; Bone Marrow; Hematopoietic System; Leukemia; Radiation; Radioisotopes | 1953 |
[Radioactive phosphorus and radioactive arsenic in the treatment of malignant blood diseases].
Topics: Arsenic; Hematologic Diseases; Hodgkin Disease; Humans; Leukemia; Phosphorus; Polycythemia Vera; Radioisotopes | 1952 |
[Modern status of arsenic in the treatment of leukemia].
Topics: Arsenic; Humans; Leukemia | 1957 |
[Comparative evaluation of the effectiveness of certain therapeutic methods in chronic leukemias; roentgen rays, radioactive phosphorus, urethane, embichine, arsenic, myleran. IV].
Topics: Arsenic; Busulfan; Chronic Disease; Leukemia; Phosphorus; Phosphorus, Dietary; Radioactivity; Urethane; X-Rays | 1959 |
[Comparative evaluation of the effectiveness of certain therapeutic methods in chronic leukemias; roentgen rays, radioactive phosphorus, urethane, embichine, arsenic, myleran. V].
Topics: Arsenic; Busulfan; Chronic Disease; Leukemia; Phosphorus; Phosphorus, Dietary; Radioactivity; Urethane; X-Rays | 1959 |
NEPHROCUTANEOUS SYNDROMES.
Topics: Amyloidosis; Anemia; Anemia, Sickle Cell; Angiokeratoma; Arachnodactyly; Arsenic; Blood Protein Disorders; Collagen Diseases; Dermatology; Drug Hypersensitivity; Ehlers-Danlos Syndrome; Glomerulonephritis; Humans; Kidney Diseases; Leukemia; Lupus Erythematosus, Systemic; Marfan Syndrome; Metabolic Diseases; Multiple Myeloma; Neurofibromatoses; Pseudoxanthoma Elasticum; Purpura; Pyelonephritis; Skin Neoplasms; Toxicology; Tuberous Sclerosis; Vascular Diseases | 1964 |
[Treatment of leukemia with arsenic plus sulfonamide preparations].
Topics: Arsenic; Leukemia; Sulfanilamide; Sulfanilamides; Sulfonamides | 1962 |
The use of radioarsenic (As76) in the treatment of leucemia and allied disorders of the hematopoietic tissues.
Topics: Arsenic; Arylsulfonates; Elements, Radioactive; Leukemia | 1948 |
[Arsenic, leukemia and old horses].
Topics: Arsenic; Fatigue Syndrome, Chronic; Humans; Leukemia; Trace Elements | 1999 |
Arsenic suppresses necrosis induced by selenite in human leukemia HL-60 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic; Cations; DNA-Binding Proteins; DNA, Neoplasm; Drug Interactions; Heat Shock Transcription Factors; HL-60 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia; Mitogen-Activated Protein Kinases; Necrosis; NF-kappa B; Signal Transduction; Sodium Selenite; Transcription Factor AP-1; Transcription Factors | 2001 |
Expression of HSP-28 and three HSP-70 genes during the development and decay of thermotolerance in leukemic and nonleukemic human tumors.
Topics: Arsenic; Arsenites; Base Sequence; Cell Survival; Electrophoresis, Gel, Two-Dimensional; Gene Expression; Heat-Shock Proteins; Hot Temperature; Humans; Hyperthermia, Induced; In Vitro Techniques; Leukemia; Molecular Sequence Data; Neoplasms; Oligodeoxyribonucleotides; Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sodium Compounds; Tumor Cells, Cultured | 1991 |
The human 32-kDa stress protein induced by exposure to arsenite and cadmium ions is heme oxygenase.
Topics: Anions; Arsenic; Arsenites; Cadmium; Cations; Cobalt; Electrophoresis, Polyacrylamide Gel; Heat-Shock Proteins; HeLa Cells; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Hot Temperature; Humans; Immunoblotting; Leukemia; Mixed Function Oxygenases; Molecular Weight; Tumor Cells, Cultured | 1989 |
[Therapy related changes in leukemias].
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic; Chemical and Drug Induced Liver Injury; Cushing Syndrome; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leukemia; Male; Middle Aged; Osteosclerosis; Peptic Ulcer; Prednisone; Radiotherapy; Sepsis; Thromboembolism; Transfusion Reaction | 1967 |